Rules-Based Medicine Gets $1.1M SBIR Grant to Develop 50 Cancer Biomarker Assays | GenomeWeb

Rules-Based Medicine Gets $1.1M SBIR Grant to Develop 50 Cancer Biomarker Assays

Oct 10, 2007

NEW YORK (GenomeWeb News) — The National Cancer Institute has given Rules-Based Medicine a $1.1 million Phase I/Phase II Small Business Innovation Research contract to develop immunoassays for cancer, the biomarker testing company said today.

Austin, Texas-based RBM said it will use the cash to develop 50 new quantitative, multiplexed immunoassays for cancer-related proteins to add to its Human Multi-Analyte Profile platform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Laureates Warn Against Hard Brexit

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

For All

Vox reports on inequities in genetic research and efforts to address them.

Lawrence Krauss to Retire Following Sexual Misconduct Allegations

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

This Week in PNAS

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.